Leukemic stem cells hijack lineage inappropriate signalling pathways to promote their growth
Leukemic stem cells hijack lineage inappropriate signalling pathways to promote their growth
复制标题
DOI:
10.1101/2023.03.10.532081
复制
发表时间:
2023-04
期刊:
影响因子:
--
通讯作者:
S. Kellaway;S. Potluri;P. Keane;H. Blair;P. Chin;A. Ptasinska;Alice Worker;L. Ames;Assunta Adamo;D. Coleman;Naeem Khan;Salam A. Assi;A. Krippner-Heidenreich;M. Raghavan;P. Cockerill;O. Heidenreich;C. Bonifer
中科院分区:
文献类型:
--
作者:
S. Kellaway;S. Potluri;P. Keane;H. Blair;P. Chin;A. Ptasinska;Alice Worker;L. Ames;Assunta Adamo;D. Coleman;Naeem Khan;Salam A. Assi;A. Krippner-Heidenreich;M. Raghavan;P. Cockerill;O. Heidenreich;C. Bonifer
Acute Myeloid Leukemia (AML) is caused by multiple mutations which dysregulate growth and differentiation of myeloid cells. Cells adopt different gene regulatory networks specific to individual mutations, maintaining a rapidly proliferating blast cell population with fatal consequences for the patient if not treated. The most common treatment option is still chemotherapy which targets such cells. However, patients harbour a population of quiescent leukemic stem cells (LSCs) which can emerge from quiescence to trigger relapse after therapy. The processes that allow such cells to re- grow remain unknown. Here, we examined the well characterised t(8;21) AML sub-type as a model to address this question. Using a novel t(8;21) patient-derived xenograft model, we show that t(8;21) LSCs aberrantly activate the VEGF and IL-5 signalling pathways. Both pathways operate within a regulatory circuit consisting of the driver oncoprotein RUNX1::ETO and an AP-1/GATA2 axis allowing LSCs to re-enter the cell cycle while preserving self-renewal capacity.